NCT03071406 2026-03-11
Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
Clinical Trials
57 trialsNCT04771520 2026-03-02
Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT01659151 2026-02-20
Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT07405086 2026-02-12
Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
OHSU Knight Cancer Institute
Phase 2 Not yet recruiting
NCT07340619 2026-01-14
EPIBREAST
UNICANCER
Phase 2 Not yet recruiting
NCT02374242 2025-12-10
ABC
Melanoma Institute Australia
Phase 2 Active not recruiting
NCT05282901 2025-11-24
PLUME
Institut Curie
Phase 2 Active not recruiting
NCT05169437 2025-10-29
PAVO
Tempus AI
Phase 2 Terminated
NCT03915678 2025-10-06
AGADIR
Institut BergoniƩ
Phase 2 Recruiting
NCT04792073 2025-08-11
Study of Avelumab and/or Radiation Therapy in People With Advanced Merkel Cell Carcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT03898908 2025-05-21
EBRAIN-MEL
Grupo EspaƱol Multidisciplinar de Melanoma
Phase 2 Completed
NCT01864538 2025-05-11
A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma
ImmunoGenesis
Phase 2 Terminated
NCT06101134 2025-04-14
A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations
Bristol-Myers Squibb
Phase 2 Active not recruiting
NCT04629339 2025-03-13
Study of INCB086550 in Select Solid Tumors
Incyte Corporation
Phase 2 Terminated
NCT03991130 2025-02-06
High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma
University of California, San Diego
Phase 2 Terminated
NCT01009177 2025-02-03
Effect of Bosentan in Patients With Metastatic Melanoma Treated With Dacarbazine (DTIC)
Actelion
Phase 2 Completed
NCT01884961 2025-01-13
IL2HD
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 2 Completed
NCT00445965 2024-04-04
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT02831933 2023-09-21
ENSIGN
The Methodist Hospital Research Institute
Phase 2 Terminated
NCT00003308 2023-06-22
Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT05561491 2023-06-22
A Study of ONCOS-102 in Combination With Other Novel Immune-therapies in Advanced Treatment-resistant Melanoma Patients
Targovax ASA
Phase 2 Withdrawn
NCT05077280 2022-12-06
A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma
California Pacific Medical Center Research Institute
Phase 2 Recruiting
NCT02115139 2022-11-08
GRAY-B
Grupo EspaƱol Multidisciplinar de Melanoma
Phase 2 Completed
NCT02218164 2022-10-07
Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT01335009 2021-09-01
Efficacy Study of Pharmacokinetic(PK)/Pharmacodynamic(PD) Relationship of Monotherapy MORAb-004 in Metastatic Melanoma
Eisai Inc.
Phase 2 Completed
NCT00960752 2021-08-13
Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01967823 2021-03-24
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00706238 2020-10-08
MAGE-A3 Antigen-Specific Cancer Immunotherapeutic in Patients With Progressive Metastatic Cutaneous Melanoma
GlaxoSmithKline
Phase 2 Terminated
NCT03013101 2020-09-30
Safety and Efficacy of Recombinant Humanized Anti-PD-1 mAb for Patients With Locally Advanced or Metastatic Melanoma
Shanghai Junshi Bioscience Co., Ltd.
Phase 2 Unknown
NCT04184518 2020-06-02
CEDUVEAL-M
Grupo EspaƱol Multidisciplinar de Melanoma
Phase 2 Withdrawn
NCT01363206 2020-03-19
GIPI
Northern California Melanoma Center
Phase 2 Completed
NCT01369875 2019-12-10
Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00670748 2019-11-19
Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT01883323 2019-11-08
Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy Following Cyclophosphamide And Fludarabine In Patients With Melanoma
University Health Network, Toronto
Phase 2 Completed
NCT01551459 2019-10-29
SUAVE
The Clatterbridge Cancer Centre NHS Foundation Trust
Phase 2 Completed
NCT01876212 2019-08-22
Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma
University of Pittsburgh
Phase 2 Completed
NCT01034787 2017-10-27
Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal Melanoma
AHS Cancer Control Alberta
Phase 2 Completed
NCT02452294 2017-05-03
BUMPER
University Hospital Tuebingen
Phase 2 Unknown
NCT00093119 2017-04-26
Trial of ABI-007 in Previously Treated Patients With Metastatic Melanoma
Celgene
Phase 2 Completed
NCT01551693 2017-04-12
STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT01754376 2017-04-12
Combined BRAF-Targeted Therapy & Immunotherapy for Melanoma
Massachusetts General Hospital
Phase 2 Terminated
NCT00550654 2017-01-13
Conformal Radiation Therapy in Treating Patients With Metastatic Cancer Outside the Brain
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00005610 2016-07-13
Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT02062359 2016-06-24
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT01565837 2016-02-01
SART
Comprehensive Cancer Centers of Nevada
Phase 2 Unknown
NCT01253096 2014-11-20
Intratumoral Application of L19IL2 in Patients With Malignant Melanoma
Philogen S.p.A.
Phase 2 Completed
NCT00299689 2014-09-05
Phase II Trial of Ontak With Metastatic Melanoma
James Graham Brown Cancer Center
Phase 2 Completed
NCT00121420 2014-05-09
Study of Motexafin Gadolinium With Whole Brain Radiation Therapy Followed by Stereotactic Radiosurgery Boost in the Treatment of Patients With Brain Metastases
Pharmacyclics LLC.
Phase 2 Terminated
NCT01055522 2014-02-25
Clinical Study Phase II of L19IL2 in Combination With Dacarbazine in Patients With Metastatic Melanoma
Philogen S.p.A.
Phase 2 Terminated
NCT00003911 2013-01-31
S9903: Whole Brain Radiotherapy Followed By Stereotactic Radiosurgery for Limited Malignant Melanoma Brain Metastases
SWOG Cancer Research Network
Phase 2 Terminated